Citations

Clear

813 citation(s) found for "He, Helen".

Sexual Medicine Society of North America (SMSNA)/American Urological Association (AUA) telemedicine and men’s health white paper
Khera, Mohit , Bernie, Helen L. , Carrier, Serge , Faraday, Martha M., Köhler, Tobias , Jenkins, Lawrence C. , Watter, Daniel N., Mulhall, John P. , Rubin, Rachel , Spitz, Aaron, Yafi, Faysal A. , Sadeghi‐Nejad, Hossein , Broderick, Gregory, Jenkins, Lawrence , Broderick, Gregory A. , Raheem, Omer A. , Ramasamy, Ranjith

Mayo Clinic

The Journal of Sexual Medicine | March 2, 2024 | Volume: 21 | Issue: 4 | Pages: 318-332

10.1093/jsxmed/qdad151 | PMID 38430132 Get It

Abstract Purpose The purpose of this white paper is to educate health care professionals about the evolution of telemedicine (TM) and to propose a hybrid model that leverages the strengths of traditional in-person medicine as well as virtual medicine while maximizing the safety and quality of men’s sexual health care. Literature Search Strategy A literature search focused on the use of TM in urology and men’s health was performed through PubMed/MEDLINE, Embase, and Web of Science (January 1, 2012–April 26, 2022). Keywords included all known permutations of the terminology used to refer to virtual health, care as well as the terminology used to refer to urologic diseases, issues specific to men’s health, and men’s sexual health concerns. Publications that emerged after the literature search that met this criterion also were incorporated. Opinion pieces, letters to the editor, meeting abstracts, and conference proceedings were excluded. Additional resources were retrieved, such as governmental technical reports, legislative updates and reviews, and blogs. This search strategy yielded 1684 records across databases after removal of duplicates. Abstracts from the retrieved records were reviewed for relevance. Relevant publications were defined as those that reported data on any aspect of TM use specific to urology, men’s health, and/or men’s sexual health. If relevance was unclear from the abstract, then the full text of the article was retrieved for a more detailed review. In addition, the published evidence-based practice guidelines relevant to care for erectile dysfunction, Peyronie’s disease, ejaculatory dysfunction, and hypogonadism were retrieved. The most common reasons for article exclusions were a focus on TM use in disciplines other than urology and the absence of data (ie, opinion pieces). After exclusions, a total of 91 publications remained and constituted the evidence base for this paper.
The Revolution in Germline DNA Testing: Actionable Takeaways from the 2023 Precision Oncology Summit
Abuali, Inas , Dubard-Gault, Marianne , Abrams, Hannah R. , Khan, Abdul Moiz , Riaño, Ivy , Münster, Pamela N. , Yadav, Siddhartha

Mayo Clinic

International Journal of Cancer Care and Delivery | February 28, 2024 | Volume: 4 | Issue: 1 | Pages: No page available

10.53876/001c.94045 Get It

The 2023 Precision Oncology Summit was held in San Francisco on October 7 th and 8 th , focusing on actionable strategies addressing personalized treatment to improve patient outcomes. This manuscript summarizes the discussion and key learning points from “The Revolution in Germline DNA Testing” session.
Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Shah, Neil P. , Bhatia, Ravi , Altman, Jessica K. , Amaya, Maria L. , Begna, Kebede H. , Berman, Ellin , Clements, Joan , Collins, Robert H. , Curtin, Peter , Drazer, Michael W. , Maness, Lori J., Metheny, Leland , Moore, Joseph O., Oehler, Vivian G. , Pratz, Keith W. , Pusic, Iskra , Rose, Michal G., Shomali, William , Styler, Michael , Tanaka, Tiffany , Tantravahi, Srinivas K. , Thompson, James E. , Tsai, Steven , Vaughn, Jennifer E. , Welborn, Jeanna, Yang, David T. , Sundar, Hema, Gregory, Kristina M., Drazer, Michael , Bhatia, Ravi , Chan, Onyee , DeAngelo, Daniel J. , Mohan, Sanjay , Smith, B. Douglas , Talpaz, Moshe , Amaya, Maria

Mayo Clinic

Journal of the National Comprehensive Cancer Network | February 23, 2024 | Volume: 22 | Issue: 1 | Pages: 43-69

10.6004/jnccn.2024.0007 | PMID 38394770 Get It

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase–CML. The primary goal of TKI therapy in patients with chronic phase–CML is to prevent disease progression to accelerated phase–CML or blast phase–CML. Discontinuation of TKI therapy with careful monitoring is feasible in selected patients. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with chronic phase–CML.
(079) Stripping vs Ligation of Vas Deferens in Microscopic Denervation of Spermatic Cord in Men with Chronic Orchialgia: A Multicenter Study
El‐Achkar, Adnan , Hammad, Mustafa , Barham, David , Hsieh, Michael H. , Ziegelmann, Matthew , Smith, Ryan P. , Bernie, Helen L. , Raheem, O., Hotaling, James M. , Yafi, Faysal A. , Hammad, Muhammed , Hammad, Muhammed A M , Hammad, M, Mills, James L. , Raheem, O, Fendereski, Kiarad

Mayo Clinic

The Journal of Sexual Medicine | February 6, 2024 | Volume: 21 | Issue: Supplement_1 | Pages: No page available

10.1093/jsxmed/qdae001.075 Get It

Abstract Introduction Microdenervation of the spermatic cord (MSCD) is an effective treatment modality for men with intractable scrotal content pain. For patients not interested in preserving fertility, some centers advocate ligation of the vas during denervation while others perfer stripping of the Vas deferens to preserve the vasal artery, hence preserving vasculature to testis and possibly decreasing post operative congestion pain. Objective This multicenter study analyzes outcomes of patients that underwent MSCD by either stripping or ligating the vas deferens Methods A retrospective chart review of 85 patients who underwent MSCD from 2020-2023 was performed. Patients’ demographics including history of prior surgical procedures was recorded. Response to surgery was evaluated as either complete resolution of pain, partial resolution of pain or no improvement in pain. Results 85 patients underwent MSCD with a median (IQR) age of 36 (25.5-46.5) years and median duration of pain of 16 months. 37 patients underwent stripping of vas while 48 underwent ligation of vas during MSCD. Median follow up was 12 months. 21(43.5%) patients had prior inguinal scrotal surgery in ligation group compared to 5 (13.5%) in the stripping group p=0.003. The etiology of pain was similar between the groups. The response to MSCD between the 2 groups was similar (p=0.968), with similar post op complications (Table 1). Conclusions In men with intractable chronic scrotal content with no interest in preserving fertility, ligation or stripping of the vas deferens yields similar outcomes with regards to pain resolution. Both techniques are safe with no reports of any testicular atrophy. Disclosure No.
Diabetes screening outcomes in youth presenting for paediatric weight management: A report of the Paediatric Obesity Weight Evaluation Registry
Kumar, Seema , King, Eileen, Binns, Helen J. , Christison, Amy L. , Cuda, Suzanne , Joseph, Madeline , Kirk, Shelley, Christison, Amy , Yee, Jennifer K.

Mayo Clinic

Pediatric Obesity | February 1, 2024 | Volume: 19 | Issue: 4 | Pages: No page available

10.1111/ijpo.13102 | PMID 38296252 Get It

SummaryObjectiveRising prevalence of obesity has led to increased rates of prediabetes and diabetes mellitus (DM) in children. This study compares rates of prediabetes and diabetes using two recommended screening tests (fasting plasma glucose [FPG] and haemoglobin A1c [HbA1c]).Study DesignData were collected prospectively from 37 multi‐component paediatric weight management programs in POWER (Paediatric Obesity Weight Evaluation Registry).ResultsFor this study, 3962 children with obesity without a known diagnosis of DM at presentation and for whom concurrent measurement of FPG and HbA1c were available were evaluated (median age 12.0 years [interquartile range, IQR 9.8, 14.6]; 48% males; median body mass index 95th percentile [%BMIp95] 134% [IQR 120, 151]). Notably, 10.7% had prediabetes based on FPG criteria (100–125 mg/dL), 18.6% had prediabetes based on HbA1c criteria (5.7%–6.4%), 0.9% had DM by FPG abnormality (≥126 mg/dL) and 1.1% had DM by HbA1c abnormality (≥6.5%). Discordance between the tests was observed for youth in both age groups (10–18 years [n = 2915] and age 2–9 years [n = 1047]).ConclusionThere is discordance between FPG and HbA1c for the diagnosis of prediabetes and DM in youth with obesity. Further studies are needed to understand the predictive capability of these tests for development of DM (in those diagnosed with prediabetes) and cardiometabolic risk.
Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper
Perucca, Emilio , French, Jacqueline A. , Aljandeel, Ghaieb , Balestrini, Simona , Braga, Patrícia , Burneo, Jorge G. , Charway‐Felli, Augustina , Cross, J. Helen , Galanopoulou, Aristea S. , Jain, Satish , Jiang, Yuwu , Kälviäinen, Reetta , Lim, Shih Hui , Meador, Kimford J. , Mogal, Zarine , Nabbout, Rima , Sofia, Francesca , Triki, Chahnez , Walker, Matthew C. , Wiebe, Samuel , Wilmshurst, Jo M. , Yacubian, Elza Márcia Targas , Kapur, Jaideep , Felli, Augustina Charway , Somerville, Ernest , Sperling, Michael R , Triki, Chahnez , Trinka, Eugen , Walker, Matthew C , Wiebe, Samuel , Wilmshurst, Jo M , Wirrell, Elaine C , Yacubian, Elza Márcia , Kapur, Jaideep , Galanopoulou, Aristea , Cross, Helen J , Perucca, Emilio , French, Jacqueline , Balestrini, Simona , Meador, Kimford J , Burneo, Jorge G , Jain, Satish , Somerville, Ernest , Sperling, Michael R. , Trinka, Eugen , Wirrell, Elaine

Mayo Clinic

Epilepsia | January 27, 2024 | Volume: 65 | Issue: 3 | Pages: 533-541

10.1111/epi.17877 | PMID 38279786 Get It

Abstract A variety of terms, such as “antiepileptic,” “anticonvulsant,” and “antiseizure” have been historically applied to medications for the treatment of seizure disorders. Terminology is important because using terms that do not accurately reflect the action of specific treatments may result in a misunderstanding of their effects and inappropriate use. The present International League Against Epilepsy (ILAE) position paper used a Delphi approach to develop recommendations on English‐language terminology applicable to pharmacological agents currently approved for treating seizure disorders. There was consensus that these medications should be collectively named “antiseizure medications”. This term accurately reflects their primarily symptomatic effect against seizures and reduces the possibility of health care practitioners, patients, or caregivers having undue expectations or an incorrect understanding of the real action of these medications. The term “antiseizure” to describe these agents does not exclude the possibility of beneficial effects on the course of the disease and comorbidities that result from the downstream effects of seizures, whenever these beneficial effects can be explained solely by the suppression of seizure activity. It is acknowledged that other treatments, mostly under development, can exert direct favorable actions on the underlying disease or its progression, by having “antiepileptogenic” or “disease‐modifying” effects. A more‐refined terminology to describe precisely these actions needs to be developed.
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19)
Aggarwal, Rahul , Hillman, David W. , Xiao, Han , Picus, Joel , Taplin, Mary‐Ellen , Dorff, Tanya B. , Appleman, Leonard J. , Weckstein, Douglas, Patnaik, Akash , Bryce, Alan H. , Shevrin, Daniel H. , Mohler, James L. , Anderson, D. Mark , Tan, Alan , Halabi, Susan , Dooley, Katharine , O’Brien, Patrick, Ryan, Charles J. , Eggener, Scott E. , Dakhil, Shaker R. , Smith, Raymond E., Gartrell, Benjamin A. , Fagbemi, Seth O., Mowat, Rex B., Hashemi, Neda , Humeniuk, Michael, Ellerton, John , Olsen, Mark R., Wang, Jennifer , Pascual, Sheila, Randall, James M., Kilari, Deepak , Najera, Jose Eugenio, Rowland, Kendrith M. , Hauke, Ralph J. , Shehadeh, N. J., Curti, Brendan D. , Sheh, Bryant C., Basnet, Alina , Gross, Howard M., Hillman, David W , Xiao, Han , Picus, Joel , Dorff, Tanya , Appleman, Leonard , Patnaik, Akash , Bryce, Alan H , Shevrin, Daniel , Mohler, James , Rao, Arpit , Tagawa, Scott T , Halabi, Susan , Dooley, Katharine , O'Brien, Patrick, Chen, Ronald , Eggener, Scott , Morris, Michael J , Heller, Glenn , Anderson, Daniel, Tagawa, Scott T. , O'Brien, Patrick, Chen, Ronald C. , Morris, Michael J. , Kim, Charles , Whang, Young E. , Farber, Charles R. , King, David, Monk, Paul , Bitting, Rhonda L. , Gupta, Gopal N. , Collins, Timothy, Beer, Tomasz M. , Tate, David J. , Conway, James, Goodman, Michael Moses

Mayo Clinic

Journal of Clinical Oncology | January 24, 2024 | Volume: 42 | Issue: 10 | Pages: 1114-1123

10.1200/jco.23.01157 | PMID 38261983 Get It

PURPOSE Patients with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy and a short PSA doubling time are at risk for distant metastases. Apalutamide, an androgen receptor antagonist, and abiraterone acetate plus prednisone (AAP) prolong survival in the metastatic setting. We evaluated whether intensification of androgen-deprivation therapy (ADT) improves outcomes in BRPC. PATIENTS AND METHODS PRESTO is a randomized phase III, open-label trial in patients with BRPC and PSA doubling time ≤9 months (ClinicalTrials.gov identifier: NCT03009981 ). Patients were randomly assigned 1:1:1 to receive a finite 52-week treatment course with ADT control, ADT + apalutamide, or ADT + apalutamide + AAP. The primary end point was PSA progression-free survival (PSA-PFS), defined as serum PSA >0.2 ng/mL after treatment completion. RESULTS Five hundred three patients were enrolled. The median PSA was 1.8 ng/mL (IQR, 1.0-3.6). At the first planned interim analysis, both experimental arms significantly prolonged PSA-PFS compared with the control arm (median, 24.9 months for ADT + apalutamide v 20.3 months for ADT; hazard ratio [HR], 0.52 [95% CI, 0.35 to 0.77]; P = .00047; median, 26.0 months for ADT + apalutamide + AAP v 20.0 months for ADT; HR, 0.48 [95% CI, 0.32 to 0.71]; P = .00008). Median time to testosterone recovery did not differ across treatment arms. The most common grade ≥3 adverse event was hypertension (7.5%, 7.4%, and 18% in ADT, ADT + apalutamide, and ADT + apalutamide + AAP arms, respectively). CONCLUSION Intensified AR blockade for a finite duration prolongs PSA-PFS with a manageable safety profile, without adversely affecting time to testosterone recovery. The addition of apalutamide to ADT should be considered in patients with high-risk BRPC.
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors
Pilbeam, Kristy , Pradhan, Kamnesh R. , Croop, James M. , Liu, Xiaowei , Voss, Stephan D. , Isikwei, Emasenyie , Fox, Elizabeth , Weigel, Brenda J. , Pilbeam, Kristy L , Voss, Stephan D , Minard, Charles G. , Berg, Stacey L. , Reid, Joel M.

Mayo Clinic

Pediatric Blood & Cancer | January 8, 2024 | Volume: 71 | Issue: 3 | Pages: No page available

10.1002/pbc.30817 | PMID 38189770 Get It

AbstractBackgroundRamucirumab is a monoclonal antibody that binds the extracellular domain of vascular endothelial growth factor receptor (VEGFR‐2) and prevents binding of VEGF ligands. Based on population pharmacokinetic (PK) analysis and correlation with efficacy in adults, a target steady state trough concentration (Css,min) ≥ 50 µg/mL was established.ProceduresThis phase 1 trial (ADVL1416) used a rolling six design and a PK primary endpoint to define the recommended phase 2 dose (RP2D) of ramucirumab in children with recurrent/refractory solid tumors. Two dose levels (DL) were planned (DL1: 8 mg/kg, DL2: 12 mg/kg administered intravenously [IV] every 2 weeks). Toxicity during the initial 6 weeks was used to assess maximum tolerated dose (MTD). Cycle 1 Day 42 trough (Cmin) ≥ 50 µg/mL was the target concentration for the PK endpoint. At the RP2D, cohorts for PK expansion and children with central nervous tumors were planned.ResultsTwenty‐nine patients were enrolled; 28 were eligible; median age [range] = 13.5 [1–21] years; 22 were evaluable for the PK endpoint. Dose‐limiting proteinuria occurred at both DLs; however, the MTD was not exceeded. At DL2 (12 mg/kg), the median Day 42 Cmin (n = 16) was 87.8 µg/mL; 15 of 16 patients achieved a Cmin ≥ 50 µg/mL.ConclusionRamucirumab was well tolerated in children and adolescents with solid tumors. The RP2D for ramucirumab was 12 mg/kg IV every 2 weeks. This trial demonstrates the feasibility of incorporating a primary PK endpoint to determine dose escalation and the RP2D in children. Studies of ramucirumab in children with selected solid tumors are ongoing.
Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce
Willis, Zachary , Oliveira, Carlos R. , Abzug, Mark J., Anosike, Brenda I. , Ardura, Monica I. , Bio, Laura , Boguniewicz, Juri , Downes, Kevin J. , Grapentine, Steven P, Hersh, Adam L. , Heston, Sarah M. , Hijano, Diego R. , James, Scott H. , Jones, Sarah Bruyn, Lockowitz, Christine R , Lloyd, Elizabeth C , MacBrayne, Christine E. , Marón, Gabriela , Hayes, Molly , Miller, Christine M , Morton, Ted , Olivero, Rosemary , Schwenk, Hayden T. , Soma, Vijaya L, Vora, Surabhi B , Nakamura, Mari , Wolf, Joshua , Willis, Zachary I , Bio, Laura L , Downes, Kevin J , Heston, Sarah M , Hijano, Diego R , Hayes McDonough, Molly , Miller, Christine M , Schwenk, Hayden T , Nakamura, Mari M , Wolf, Joshua , Boguniewicz, Juri , Oliveira, Carlos R , Chiotos, Kathleen , Huskins, W. Charles , Jones, Sarah, Orscheln, Rachel C. , Singh, Prachi , Sue, Paul K.

Mayo Clinic

Journal of the Pediatric Infectious Diseases Society | December 27, 2023 | Volume: 13 | Issue: 3 | Pages: 159-185

10.1093/jpids/piad116 | PMID 38339996 Get It

Abstract Background Since November 2019, the SARS-CoV-2 pandemic has created challenges for preventing and managing COVID-19 in children and adolescents. Most research to develop new therapeutic interventions or to repurpose existing ones has been undertaken in adults, and although most cases of infection in pediatric populations are mild, there have been many cases of critical and fatal infection. Understanding the risk factors for severe illness and the evidence for safety, efficacy, and effectiveness of therapies for COVID-19 in children is necessary to optimize therapy. Methods A panel of experts in pediatric infectious diseases, pediatric infectious diseases pharmacology, and pediatric intensive care medicine from 21 geographically diverse North American institutions was re-convened. Through a series of teleconferences and web-based surveys and a systematic review with meta-analysis of data for risk factors, a guidance statement comprising a series of recommendations for risk stratification, treatment, and prevention of COVID-19 was developed and refined based on expert consensus. Results There are identifiable clinical characteristics that enable risk stratification for patients at risk for severe COVID-19. These risk factors can be used to guide the treatment of hospitalized and non-hospitalized children and adolescents with COVID-19 and to guide preventative therapy where options remain available.
Isatuximab Monotherapy for Desensitization in Highly Sensitized Patients Awaiting Kidney Transplant
Vincenti, Flavio , Bestard, Oriol , Brar, Amarpali, Cruzado, Josep M. , Serón, Daniel , Gaber, A. Osama , Ali, Nicole , Tambur, Anat R. , Lee, Helen , Abbadessa, Giovanni , Paul, Jo-Anne, Dudek, Markus , Siegel, Ruby J. , Torija, Alba , Sémiond, Dorothée, Lépine, Lucie, Ternès, Nils, Stegall, Mark, Gaber, Ahmed Osama , Bestard, Oriol , Montgomery, Robert A. , Stegall, Mark D.

Mayo Clinic

Journal of the American Society of Nephrology | December 26, 2023 | Volume: 35 | Issue: 3 | Pages: 347-360

10.1681/asn.0000000000000287 | PMID 38147137 Get It

Significance Statement There is no standardized desensitization regimen for kidney transplant candidates. CD38, expressed by plasma cells, could be targeted for desensitization to deplete plasma cells producing alloantibodies and donor-specific antibodies. Few studies and case reports are available regarding the use of CD38 antibodies for desensitization in patients awaiting kidney transplant. This study shows that isatuximab, a CD38-targeting therapy, was well tolerated in kidney transplant candidates, with a durable decrease in anti-HLA antibodies and partial desensitization activity. The short treatment period and long follow-up of this study allowed for the understanding of the mechanism and timing for any antibody rebound. Isatuximab could be further investigated as an option for adjunct therapy to existing desensitization for patients on the kidney transplant waitlist. Background Patients with calculated panel reactive antibody (cPRA) ≥80.00%, particularly those with cPRA ≥99.90%, are considered highly sensitized and underserved by the Kidney Allocation System. Desensitization removes circulating reactive antibodies and/or suppresses antibody production to increase the chances of a negative crossmatch. CD38 is expressed highly on plasma cells, thus is a potential target for desensitization. Methods This was an open-label single-arm phase 1/2 study investigating the safety, pharmacokinetics, and preliminary efficacy of isatuximab in patients awaiting kidney transplantation. There were two cohorts, cohorts A and B, which enrolled cPRA ≥99.90% and 80.00% to <99.90%, respectively. Results Twenty-three patients (12 cohort A, 11 cohort B) received isatuximab 10 mg/kg weekly for 4 weeks then every 2 weeks for 8 weeks. Isatuximab was well tolerated with pharmacokinetic and pharmacodynamic profiles that indicated similar exposure to multiple myeloma trials. It resulted in decreases in CD38 + plasmablasts, plasma cells, and NK cells and significant reductions in HLA-specific IgG-producing memory B cells. Overall response rate, on the basis of a predefined composite desensitization end point, was 83.3% and 81.8% in cohorts A and B. Most responders had decreases in anti-HLA antibodies that were maintained for 26 weeks after the last dose. Overall, cPRA values were minimally affected, however, with only 9/23 patients (39%) having cPRA decreases to target levels. By study cutoff (median follow-up of 68 weeks), six patients received transplant offers, of which four were accepted. Conclusions In this open-label trial, isatuximab was well tolerated and resulted in a durable decrease in anti-HLA antibodies with partial desensitization activity. Clinical Trial registration number NCT04294459.